Q1 Earnings Estimate for DTIL Issued By HC Wainwright

Precision BioSciences, Inc. (NASDAQ:DTIL) – Research analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Precision BioSciences in a research note issued to investors on Thursday, March 19th. HC Wainwright analyst P. Trucchio expects that the company will earn ($0.51) per share for the quarter. The consensus estimate for Precision BioSciences’ current full-year earnings is ($1.23) per share. HC Wainwright also issued estimates for Precision BioSciences’ Q2 2027 earnings at ($0.52) EPS, Q3 2027 earnings at ($0.53) EPS, Q4 2027 earnings at $0.03 EPS and FY2030 earnings at $1.22 EPS.

Several other research firms also recently weighed in on DTIL. Wall Street Zen upgraded Precision BioSciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Precision BioSciences in a research report on Monday, December 22nd. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $19.00 target price on shares of Precision BioSciences in a report on Friday, March 13th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $39.50.

Precision BioSciences Stock Down 3.3%

Shares of DTIL opened at $6.50 on Friday. The business’s 50 day moving average is $4.44 and its 200 day moving average is $5.05. The company has a current ratio of 13.32, a quick ratio of 13.32 and a debt-to-equity ratio of 0.24. Precision BioSciences has a 12-month low of $3.53 and a 12-month high of $8.82. The company has a market capitalization of $160.62 million, a PE ratio of -1.27 and a beta of 1.28.

Insiders Place Their Bets

In other Precision BioSciences news, CFO John Alexander Kelly sold 15,213 shares of Precision BioSciences stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $4.03, for a total transaction of $61,308.39. Following the completion of the transaction, the chief financial officer directly owned 106,448 shares of the company’s stock, valued at $428,985.44. The trade was a 12.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider J. Jefferson Smith sold 10,200 shares of the business’s stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $4.03, for a total transaction of $41,106.00. Following the transaction, the insider owned 110,184 shares in the company, valued at $444,041.52. This trade represents a 8.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 93,845 shares of company stock valued at $376,677 over the last three months. 4.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Precision BioSciences

Hedge funds have recently added to or reduced their stakes in the company. Occudo Quantitative Strategies LP bought a new stake in Precision BioSciences in the fourth quarter worth about $52,000. Engineers Gate Manager LP bought a new position in shares of Precision BioSciences during the fourth quarter valued at approximately $43,000. Jump Financial LLC purchased a new stake in shares of Precision BioSciences in the fourth quarter worth approximately $149,000. Miller Financial Services LLC raised its holdings in shares of Precision BioSciences by 50.0% in the fourth quarter. Miller Financial Services LLC now owns 15,000 shares of the company’s stock worth $62,000 after buying an additional 5,000 shares during the period. Finally, Velan Capital Investment Management LP bought a new stake in shares of Precision BioSciences during the 3rd quarter worth approximately $110,000. 37.99% of the stock is currently owned by institutional investors.

Precision BioSciences Company Profile

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.